First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Current Assets
All assets expected to be converted to cash or used up within one year.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets remains negative
Q1 FY2026 total current assets was $289.4M, compared with $0 a year earlier.
Context
- Total current assets amounted to 99.6% of total assets at the end of Q1 FY2026.
- Total current assets increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 316.4M USD
- Year-over-year change
- -18.9%
- 2-year CAGR
- -10.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 316.4M | -18.9% |
| FY2024 | 2024-12-31 | 389.93M | -2.2% |
| FY2023 | 2023-12-31 | 398.56M | — |
Total Current Assets vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total current assets of $289.4M is the 4th highest of the 10 companies compared; the peer median is $118.4M.
- Total current assets amounts to 99.6% of total assets for TRAX, versus a peer median of 92.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $760.05M | +32.5% | +32.9% | 99.9% | |
| Mar 2026 | $396.64M | -21.7% | +76.6% | 99.1% | |
| Mar 2026 | $316.11M | -12.9% | -7.8% | 95.9% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $289.4M | — | — | 99.6% |
| Mar 2026 | $188.76M | +894.8% | -43.4% | 99.5% | |
| Jun 2026 | $118.4M | — | — | 92.2% | |
| Mar 2026 | $113.57M | -11.1% | +31.6% | 77.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $113.4M | +13.1% | -7.7% | 74.4% |
| Mar 2026 | $110.23M | +1.3% | -13.2% | 55.5% | |
| Jun 2026 | $107.94M | +1059.6% | +66.0% | 45.3% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $118.4M | +7.2% | +12.0% | 92.2% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.